VitamFero has announced a partnership agreement with Merial, the Animal Health Division of Sanofi Group, for developing new vaccines against significant production animal (...)
Articles similaires sur : "2013"
On January 10th 2013, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous (...)
VitamFero is a biotechnology firm in the Genopole cluster with a secondary facility in Tours (Indre & Loire, France) that develops novel veterinary and human vaccines against parasitic (...)
Imaxio and VitamFero announce the conclusion of an R&D partnership agreement. According to the terms of the agreement, the two firms will evaluate the combination of IMX313, Imaxio’s (...)